Share Cancellation
Hanmi Pharmaceutical decided to retire 85,316 common shares of previously acquired treasury stock on November 2, 2026.
Hanmi Pharm. Co., Ltd. Disclosures
128940 · KOSPI · Based on DART filings
Disclosures
2 total · 20 per page
Major
20261027800461
Hanmi Pharmaceutical's 3Q 2026 consolidated revenue was KRW 377.4 billion, up 4.2% year over year but down 19.2% quarter over quarter; operating profit was KRW 37.8 billion, down 31.3% and 71.2%.
Catch the next disclosure fast
Get app alerts for new disclosures from Hanmi Pharm. Co., Ltd..